ClinVar Miner

Submissions for variant NM_000070.3(CAPN3):c.338T>C (p.Ile113Thr)

gnomAD frequency: 0.00015  dbSNP: rs747026964
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000440617 SCV000335003 uncertain significance not provided 2018-07-03 criteria provided, single submitter clinical testing
GeneDx RCV000440617 SCV000533388 likely pathogenic not provided 2023-06-08 criteria provided, single submitter clinical testing Identified in the presence of a second CAPN3 variant, in a patient with early onset pelvifemoral LGMD2A, however CAPN3 enzyme deficiency was not detected (Nilsson et al., 2014).; Identified heterozygous by NGS panel testing in three patients with LGMD2A, however no second variant was identified (Nallamilli et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25079074, 30564623)
Counsyl RCV000675143 SCV000800733 uncertain significance Autosomal recessive limb-girdle muscular dystrophy type 2A 2017-09-15 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000675143 SCV000914667 uncertain significance Autosomal recessive limb-girdle muscular dystrophy type 2A 2018-01-29 criteria provided, single submitter clinical testing The CAPN3 c.338T>C (p.Ile113Thr) variant has been reported in a compound heterozygous state with a second missense variant in one patient with limb-girdle muscular dystrophy type 2A (LGMD2A) (Nilsson et al. 2014). The p.Ile113Thr is reported at a frequency of 0.000213 in the European (non-Finnish) population from the Genome Aggregation Database. The evidence for this variant is limited. The p.Ile113Thr variant is therefore considered to be of unknown clinical significance but suspicious for pathogenicity for calpainopathy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Baylor Genetics RCV000675143 SCV001529404 likely pathogenic Autosomal recessive limb-girdle muscular dystrophy type 2A criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002282100 SCV002572258 uncertain significance not specified 2022-08-23 criteria provided, single submitter clinical testing Variant summary: CAPN3 c.338T>C (p.Ile113Thr) results in a non-conservative amino acid change located in the Peptidase C2, calpain, catalytic domain (IPR001300) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 9.1e-05 in 251430 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in CAPN3 causing Limb-Girdle Muscular Dystrophy, Autosomal Recessive (9.1e-05 vs 0.0032), allowing no conclusion about variant significance. c.338T>C has been reported in the literature as a compound heterozygous genotype in at-least one individual affected with Limb-Girdle Muscular Dystrophy, Autosomal Recessive (example, Nilsson_2014) and as a VUS with a non-informative genotype (second allele not specified) in at-least three individuals within a cohort sequenced for Limb-girdle muscular dystrophies (LGMDs) at a reference laboratory (example, Nallamilli_2018). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Likely pathogenic, n=1; VUS, n=4). Based on the evidence outlined above, the variant was classified as uncertain significance.
Invitae RCV000675143 SCV002943387 uncertain significance Autosomal recessive limb-girdle muscular dystrophy type 2A 2022-11-02 criteria provided, single submitter clinical testing This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 113 of the CAPN3 protein (p.Ile113Thr). This variant is present in population databases (rs747026964, gnomAD 0.02%). This missense change has been observed in individual(s) with limb-girdle muscular dystrophy (PMID: 25079074, 30564623). ClinVar contains an entry for this variant (Variation ID: 283107). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CAPN3 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Revvity Omics, Revvity RCV000440617 SCV003828963 uncertain significance not provided 2022-07-21 criteria provided, single submitter clinical testing
Baylor Genetics RCV003475901 SCV004211503 likely pathogenic Muscular dystrophy, limb-girdle, autosomal dominant 4 2023-10-28 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000440617 SCV004227365 uncertain significance not provided 2023-06-22 criteria provided, single submitter clinical testing PM3

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.